keyword
MENU ▼
Read by QxMD icon Read
search

"FDA"

keyword
https://www.readbyqxmd.com/read/28938602/activation-of-cancerous-inhibitor-of-pp2a-cip2a-contributes-to-lapatinib-resistance-through-induction-of-cip2a-akt-feedback-loop-in-erbb2-positive-breast-cancer-cells
#1
Ming Zhao, Erin W Howard, Amanda B Parris, Zhiying Guo, Qingxia Zhao, Zhikun Ma, Ying Xing, Bolin Liu, Susan M Edgerton, Ann D Thor, Xiaohe Yang
Lapatinib, a small molecule ErbB2/EGFR inhibitor, is FDA-approved for the treatment of metastatic ErbB2-overexpressing breast cancer; however, lapatinib resistance is an emerging clinical challenge. Understanding the molecular mechanisms of lapatinib-mediated anti-cancer activities and identifying relevant resistance factors are of pivotal significance. Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a recently identified oncoprotein that is overexpressed in breast cancer. Our study investigated the role of CIP2A in the anti-cancer efficacy of lapatinib in ErbB2-overexpressing breast cancer cells...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28938590/ocular-toxicities-associated-with-targeted-anticancer-agents-an-analysis-of-clinical-data-with-management-suggestions
#2
Chen Fu, Dan S Gombos, Jared Lee, Goldy C George, Kenneth Hess, Andrew Whyte, David S Hong
Ocular toxicities are among the most common adverse events resulting from targeted anticancer agents and are becoming increasingly relevant in the management of patients on these agents. The purpose of this study is to provide a framework for management of these challenging toxicities based on objective data from FDA labels and from analysis of the literature. All oncologic drugs approved by the FDA up to March 14, 2015, were screened for inclusion. A total of 16 drugs (12 small-molecule drugs and 4 monoclonal antibodies) were analyzed for ocular toxicity profiles based on evidence of ocular toxicity...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28938421/bortezomib-alone-and-in-combination-with-salinosporamid-a-induces-apoptosis-and-promotes-pheochromocytoma-cell-death-in-vitro-and-in-female-nude-mice
#3
Petra Bullova, Antony Cougnoux, Geena Marzouca, Juraj Kopacek, Karel Pacak
Proteasome inhibitors have been frequently used in treating hematologic and solid tumors. They are administered individually or in combination with other regimens, to prevent severe side effects and resistance development. Since they have been shown to be efficient and are pharmaceutically available, we tested the first FDA-approved proteasome inhibitor bortezomib alone and in combination with another proteasome inhibitor, salinosporamid A, in pheochromocytoma cells. Pheochromocytomas/paragangliomas (PHEOs/PGLs) are neuroendocrine tumors for which no definite cure is yet available...
August 15, 2017: Endocrinology
https://www.readbyqxmd.com/read/28937865/recall-of-the-real-cost-anti-smoking-campaign-is-specifically-associated-with-endorsement-of-campaign-targeted-beliefs
#4
Elissa C Kranzler, Laura A Gibson, Robert C Hornik
Though previous research suggests the FDA's "The Real Cost" anti-smoking campaign has reduced smoking initiation, the theorized pathway of effects (through targeted beliefs) has not been evaluated. This study assesses the relationship between recall of campaign television advertisements and ad-specific anti-smoking beliefs. Respondents in a nationally representative survey of nonsmoking youths age 13-17 (n = 4,831) reported exposure to four The Real Cost advertisements and a fake ad, smoking-relevant beliefs, and nonsmoking intentions...
September 22, 2017: Journal of Health Communication
https://www.readbyqxmd.com/read/28935932/cannabidiol-attenuates-alcohol-induced-liver-steatosis-metabolic-dysregulation-inflammation-and-neutrophil-mediated-injury
#5
Yuping Wang, Partha Mukhopadhyay, Zongxian Cao, Hua Wang, Dechun Feng, György Haskó, Raphael Mechoulam, Bin Gao, Pal Pacher
Cannabidiol (CBD) is a non-psychoactive component of marijuana, which has anti-inflammatory effects. It has also been approved by FDA for various orphan diseases for exploratory trials. Herein, we investigated the effects of CBD on liver injury induced by chronic plus binge alcohol feeding in mice. CBD or vehicle was administered daily throughout the alcohol feeding study. At the conclusion of the feeding protocol, serums samples, livers or isolated neutrophils were utilized for molecular biology, biochemistry and pathology analysis...
September 21, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28935452/3d-image-guidance-assisted-identification-of-colorectal-cancer-liver-metastases-not-seen-on-intraoperative-ultrasound-results-from-a-prospective-trial
#6
T Peter Kingham, Linda M Pak, Amber L Simpson, Universe Leung, Alexandre Doussot, Michael I D'Angelica, Ronald P DeMatteo, Peter J Allen, William R Jarnagin
BACKGROUND: Neoadjuvant treatment of colorectal liver metastases has become increasingly common, and while effective, often renders small metastases difficult to visualize on intraoperative US. The objective of this study was to determine the utility of a 3D image-guidance system in patients with intraoperative sonographically-occult CRLM. METHODS: 50 patients with at least one CRLM ≤ 1.5 cm were enrolled in this prospective trial of an FDA-approved Explorer image-guidance system...
September 18, 2017: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
https://www.readbyqxmd.com/read/28935287/past-present-and-future-of-pharmacotherapy-for-obesity
#7
David Benaiges, Juan Pedro-Botet, Juana A Flores-Le Roux, Elisenda Climent, Albert Goday
Conventional treatment for obesity with diet, exercise and bariatric surgery has limitations; thus, it is necessary to have pharmacological tools. In the past, different drugs were marketed that were withdrawn due to safety problems. There are currently 3 drugs approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for obesity therapy (orlistat, combination of bupropion and delayed-release naltrexone and liraglutide) and two more only authorized by FDA (lorcaserin and the combination of phentermine and extended release topiramate)...
September 18, 2017: Clínica e Investigación en Arteriosclerosis
https://www.readbyqxmd.com/read/28935255/a-comprehensive-approach-to-qualify-and-validate-the-essential-parameters-of-an-in-vitro-release-test-ivrt-method-for-acyclovir-cream-5
#8
Katrin I Tiffner, Isadore Kanfer, Thomas Augustin, Reingard Raml, Sam G Raney, Frank Sinner
The rate of release of an active pharmaceutical ingredient (API) from a topical semisolid dosage form can be influenced by its physical and structural properties. An In Vitro Release Test (IVRT) is an established method to characterize this rate of API release and compare the underlying sameness in product quality characteristics. The purpose of this work was to validate an IVRT method to compare acyclovir cream, 5% products. However, despite widespread use of the IVRT since 1997, there was no established approach to validate an IVRT method...
September 18, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28934783/serious-adverse-events-associated-with-readmission-through-one-year-after-vertebral-augmentation-with-either-a-polyetheretherketone-implant-or-balloon-kyphoplasty
#9
Douglas P Beall, Jeffrey D Coe, Mark McIlduff, Daniel Bloch, John Hornberger, Christopher Warner, Sean Tutton
BACKGROUND: The KAST (Kiva Safety and Efficacy) investigation device exempt (IDE) study indicated that the majority of patients responded equally well to vertebral augmentation using either an implant-based approach or balloon kyphoplasty (BK). Additional investigation has suggested that a subset of patients may benefit further by avoiding repeated readmissions due to serious adverse events (SAEs) if they receive one vertebral augmentation approach over another. OBJECTIVES: The primary aim was to assess the effect of 2 different augmentation procedures on readmission rates for SAEs...
September 2017: Pain Physician
https://www.readbyqxmd.com/read/28932272/the-place-of-eluxadoline-in-the-management-of-irritable-bowel-syndrome-with-diarrhea
#10
REVIEW
Sherry Levio, Brooks D Cash
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by abdominal pain associated with defecation with altered stool frequency or stool form. The global prevalence of IBS ranges from 10% to 15% and total healthcare cost attributable to IBS is significant. Among individuals with IBS, the condition has dramatic effects on health-related quality of life, work and school productivity, and activities of daily living. It may be diagnosed with confidence, based on symptom-based diagnostic criteria, exclusion of alarm features and directed diagnostic testing...
September 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28932245/electromagnetic-fields-for-the-regulation-of-neural-stem-cells
#11
REVIEW
Mengchu Cui, Hongfei Ge, Hengli Zhao, Yongjie Zou, Yujie Chen, Hua Feng
Localized magnetic fields (MFs) could easily penetrate the scalp, skull, and meninges, thus inducing an electrical current in both the central and peripheral nervous systems, which is primarily used in transcranial magnetic stimulation (TMS) for inducing specific effects on different regions or cells that play roles in various brain activities. Studies of repetitive transcranial magnetic stimulation (rTMS) have led to novel attractive therapeutic approaches. Neural stem cells (NSCs) in adult human brain are able to self-renew and possess multidifferential ability to maintain homeostasis and repair damage after acute central nervous system...
2017: Stem Cells International
https://www.readbyqxmd.com/read/28931908/drug-release-from-core-shell-pva-silk-fibroin-nanoparticles-fabricated-by-one-step-electrospraying
#12
Yang Cao, Fengqiu Liu, Yuli Chen, Tao Yu, Deshuai Lou, Yuan Guo, Pan Li, Zhigang Wang, Haitao Ran
Silk fibroin (SF), a FDA-approved natural protein, is renowned for its great biocompatibility, biodegradability, and mechanical properties. SF-based nanoparticles provide new options for drug delivery with their tunable drug loading and release properties. To take advantage of the features of carrier polymers, we present a one-step electrospraying method that combines SF, polyvinyl alcohol (PVA) and therapeutic drugs without an emulsion process. A distinct core-shell structure was obtained with the PVA core and silk shell after the system was properly set up...
September 20, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28931515/gemtuzumab-ozogamicin-makes-a-comeback
#13
(no author information available yet)
After being pulled from the market 7 years ago, gemtuzumab ozogamicin has been reapproved by the FDA, this time for adults newly diagnosed with acute myeloid leukemia, as well as patients 2 years of age and older with relapsed/refractory disease. The CD33-targeting antibody-drug conjugate can be given as a single agent or in combination with chemotherapy.
September 20, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28931386/erratum-to-understanding-how-perceptions-of-tobacco-constituents-and-the-fda-relate-to-effective-and-credible-tobacco-risk-messaging-a-national-phone-survey-of-u-s-adults-2014-2015
#14
Marcella H Boynton, Robert P Agans, J Michael Bowling, Noel T Brewer, Erin L Sutfin, Adam O Goldstein, Seth M Noar, Kurt M Ribisl
No abstract text is available yet for this article.
September 20, 2017: BMC Public Health
https://www.readbyqxmd.com/read/28931331/an-overview-of-fda-approved-vaccines-their-innovators
#15
Rebekah H Griesenauer, Michael S Kinch
A survey of FDA-approved biologicals focused upon the development of immunotherapies over time to gain insight on the challenges and trends of vaccine development today. Areas covered: A total of 135 different immune-based therapies could be broadly divided into passive or active immunotherapies. Whereas just over half of passive immunotherapies targeted infectious diseases, the vast majority of active immunotherapy products (vaccines) were directed against a handful of viral and bacterial pathogens. We also analyze changes in vaccine strategy, including the use of viable antigens and subunit approaches...
September 21, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28931315/the-liver-toxicity-knowledge-base-lktb-and-drug-induced-liver-injury-dili-classification-for-assessment-of-human-liver-injury
#16
Shraddha Thakkar, Weida Tong, Minjun Chen, Hong Fang, Zhichao Liu, Ruth Roberts
Drug-induced liver injury (DILI) is challenging drug development, clinical practice and regulation. The Liver Toxicity Knowledge Base (LTKB) provides essential data for DILI study. Areas Covered: The LTKB provided various types of data that can be used to assess and predict DILI. Among much information available, several reference drug lists with annotated human DILI risk are of important. The LTKB DILI classification data include DILI severity concern determined by the FDA drug labeling, DILI severity score from the NIH LiverTox database, and other DILI classification schemes from the literature...
September 21, 2017: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28931213/a-review-on-the-efficacy-and-toxicity-of-different-doxorubicin-nanoparticles-for-targeted-therapy-in-metastatic-breast-cancer
#17
REVIEW
Ayman Shafei, Wesam El-Bakly, Ahmed Sobhy, Omar Wagdy, Ahmed Reda, Omar Aboelenin, Amr Marzouk, Khalil El Habak, Randa Mostafa, Mahmoud A Ali, Mahmoud Ellithy
In metastatic breast cancer (MBC), the conventional doxorubicin (DOX) has various problems due to lack of selectivity with subsequent therapeutic failure and adverse effects. DOX- induced cardiotoxicity is a major problem that necessitates the presence of new forms to decrease the risk of associated morbidity. Nanoparticles (NPs) are considered an important approach to selectively increase drug accumulation inside tumor cells and thus decreasing the associated side effects. Tumor cells develop resistance to chemotherapeutic agents through multiple mechanisms, one of which is over expression of efflux transporters...
September 16, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28931097/-approaching-new-pharmacotherapy-options-in-pain-treatment
#18
András Telekes
The evolution of medicine is noticeable in most therapeutic areas, the worse the current therapeutic result, the more quick the improvement. This is especially true in such areas that require substantial social resources, namely oncology, diabetology and CNS diseases. Pain is not a disease, it is a symptom. Pain is one of the most important components of human suffering thus it deserves special attention. In recent years new formulations of old medicines were introduced rather than new medicines. Maybe ziconitide is the last pain killer with new mechanism of action which was approved by FDA in 2004...
September 20, 2017: Magyar Onkologia
https://www.readbyqxmd.com/read/28930510/the-fate-of-fda-postapproval-studies
#19
Steven Woloshin, Lisa M Schwartz, Brian White, Thomas J Moore
Both Congress and the Food and Drug Administration (FDA) have sought to accelerate the availability of new drugs by allowing sponsors to wait to resolve many questions about safety and benefit until after their drugs receive marketing approval. As a result, most approval letters require phase 4..
September 21, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28930501/fda-oversight-of-postmarketing-studies
#20
LETTER
Mwango Kashoki, Cathryn Lee, Peter Stein
To the Editor: In their Perspective article in this issue of the Journal, Woloshin et al. raise concerns about the status of postmarketing studies after new statutory authority was provided to the Food and Drug Administration (FDA) in the FDA Amendments Act of 2007 (FDAAA). Although the authors..
September 21, 2017: New England Journal of Medicine
keyword
keyword
47310
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"